In a comment accompanying the study, Dr. Sharathkumar noted that the increased dosing frequency for younger children could be burdensome for families, leading to worse adherence, and that dosing for children heavier than 50 kg must be clarified in future studies.
“This landmark study has raised the bar for generation of level 1 evidence regarding oral anticoagulants in children,” she adds. “Clearly, this phase 2 study has enabled the successful launch of the follow-up phase 3 study, which will have a substantial effect on the clinical management of children with venous thromboembolism.”
Pages: 1 2 | Single Page
No Responses to “Phase 2 Studies Find Rivaroxaban Safe for Pediatric Venous Thromboembolism”